{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T02:27:42Z","timestamp":1793672862492,"version":"4.5.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:00:00Z","timestamp":1790208000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:00:00Z","timestamp":1790208000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s10072-026-09422-5","type":"journal-article","created":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T06:19:43Z","timestamp":1790230783000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Perampanel as a candidate for polytherapy in Stage 1 Plus status epilepticus: biological rationale and translational limits"],"prefix":"10.1007","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8187-8354","authenticated-orcid":false,"given":"Giuseppe","family":"Magro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oreste","family":"Marsico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"Saraceno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Tosto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,24]]},"reference":[{"issue":"6","key":"9422_CR1","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1111\/epi.17953","volume":"65","author":"G Magro","year":"2024","unstructured":"Magro G, Laterza V (2024) Status epilepticus: Is there a Stage 1 plus? Epilepsia 65(6):1560\u20131567. https:\/\/doi.org\/10.1111\/epi.17953","journal-title":"Epilepsia"},{"issue":"1","key":"9422_CR2","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3390\/neurolint17010011","volume":"17","author":"G Magro","year":"2025","unstructured":"Magro G (2025) Early polytherapy for probably benzodiazepine refractory na\u00efve status epilepticus (stage 1 plus). Neurol Int 17(1):11","journal-title":"Neurol Int"},{"key":"9422_CR3","doi-asserted-by":"publisher","DOI":"10.1002\/epi.70355","author":"G Magro","year":"2026","unstructured":"Magro G (2026) Stage 1 plus: a phenotype-based framework for rational polytherapy in status epilepticus. Epilepsia. https:\/\/doi.org\/10.1002\/epi.70355","journal-title":"Epilepsia"},{"issue":"8","key":"9422_CR4","doi-asserted-by":"publisher","first-page":"3081","DOI":"10.1111\/epi.18493","volume":"66","author":"CG Wasterlain","year":"2025","unstructured":"Wasterlain CG, Niquet J, Lumley L (2025) Status epilepticus: is there a stage 1 plus? Epilepsia 66(8):3081\u20133082. https:\/\/doi.org\/10.1111\/epi.18493","journal-title":"Epilepsia"},{"issue":"10","key":"9422_CR5","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1111\/epi.13121","volume":"56","author":"E Trinka","year":"2015","unstructured":"Trinka E, Cock H, Hesdorffer D et al (2015) A definition and classification of status epilepticus\u2013report of the ILAE task force on classification of status epilepticus. Epilepsia 56(10):1515\u20131523. https:\/\/doi.org\/10.1111\/epi.13121","journal-title":"Epilepsia"},{"key":"9422_CR6","doi-asserted-by":"publisher","first-page":"111894","DOI":"10.1016\/j.mehy.2026.111894","volume":"208","author":"G Magro","year":"2026","unstructured":"Magro G (2026) The Stage 1 plus hypothesis in status epilepticus: predicting resistance before it happens. Med Hypotheses 208:111894. https:\/\/doi.org\/10.1016\/j.mehy.2026.111894","journal-title":"Med Hypotheses"},{"issue":"4","key":"9422_CR7","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1002\/epi.70187","volume":"67","author":"G Magro","year":"2026","unstructured":"Magro G (2026) Stage 1 plus: toward a unified operational framework in status epilepticus. Epilepsia 67(4):2045\u20132047. https:\/\/doi.org\/10.1002\/epi.70187","journal-title":"Epilepsia"},{"issue":"Suppl 1(Suppl 1","key":"9422_CR8","doi-asserted-by":"publisher","first-page":"S35","DOI":"10.1002\/epi4.12718","volume":"8","author":"DE Naylor","year":"2023","unstructured":"Naylor DE (2023) In the fast lane: receptor trafficking during status epilepticus. Epilepsia Open 8(Suppl 1(Suppl 1)):S35-s65. https:\/\/doi.org\/10.1002\/epi4.12718","journal-title":"Epilepsia Open"},{"key":"9422_CR9","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.nbd.2012.12.015","volume":"54","author":"DE Naylor","year":"2013","unstructured":"Naylor DE, Liu H, Niquet J, Wasterlain CG (2013) Rapid surface accumulation of NMDA receptors increases glutamatergic excitation during status epilepticus. Neurobiol Dis 54:225\u2013238. https:\/\/doi.org\/10.1016\/j.nbd.2012.12.015","journal-title":"Neurobiol Dis"},{"issue":"Suppl 8(0 8)","key":"9422_CR10","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1111\/j.1528-1167.2011.03243.x","volume":"52","author":"CG Wasterlain","year":"2011","unstructured":"Wasterlain CG, Baldwin R, Naylor DE, Thompson KW, Suchomelova L, Niquet J (2011) Rational polytherapy in the treatment of acute seizures and status epilepticus. Epilepsia 52(Suppl 8(0 8)):70\u201371. https:\/\/doi.org\/10.1111\/j.1528-1167.2011.03243.x","journal-title":"Epilepsia"},{"key":"9422_CR11","doi-asserted-by":"publisher","first-page":"117368","DOI":"10.1016\/j.jns.2021.117368","volume":"423","author":"A Llaurad\u00f3","year":"2021","unstructured":"Llaurad\u00f3 A, Quintana M, Ballv\u00e9 A et al (2021) Factors associated with resistance to benzodiazepines in status epilepticus. J Neurol Sci 423:117368. https:\/\/doi.org\/10.1016\/j.jns.2021.117368","journal-title":"J Neurol Sci"},{"key":"9422_CR12","doi-asserted-by":"publisher","DOI":"10.1002\/epi.70446","author":"S Lattanzi","year":"2026","unstructured":"Lattanzi S, Giovannini G, Orlandi N, Brigo F, Trinka E, Meletti S (2026) Status epilepticus in adults: from etiology to treatment response. Epilepsia. https:\/\/doi.org\/10.1002\/epi.70446","journal-title":"Epilepsia"},{"issue":"3","key":"9422_CR13","doi-asserted-by":"publisher","first-page":"e218281","DOI":"10.1212\/wnl.0000000000218281","volume":"107","author":"S Lattanzi","year":"2026","unstructured":"Lattanzi S, Trinka E, Bosque-Varela P et al (2026) A predictive model for short-term mortality after status epilepticus: the ACARD score. Neurology. 107(3):e218281. https:\/\/doi.org\/10.1212\/wnl.0000000000218281","journal-title":"Neurology."},{"issue":"10","key":"9422_CR14","doi-asserted-by":"publisher","first-page":"e200","DOI":"10.1111\/epi.17753","volume":"64","author":"S Lattanzi","year":"2023","unstructured":"Lattanzi S, Giovannini G, Brigo F, Orlandi N, Trinka E, Meletti S (2023) Acute symptomatic status epilepticus: splitting or lumping? A proposal of classification based on real-world data. Epilepsia 64(10):e200\u2013e206. https:\/\/doi.org\/10.1111\/epi.17753","journal-title":"Epilepsia"},{"issue":"5","key":"9422_CR15","doi-asserted-by":"publisher","first-page":"e214624","DOI":"10.1212\/wnl.0000000000214624","volume":"106","author":"P De Stefano","year":"2026","unstructured":"De Stefano P, Baumann SM, Fisch U et al (2026) Impact of etiology on mortality and recovery in patients with status epilepticus. Neurology 106(5):e214624. https:\/\/doi.org\/10.1212\/wnl.0000000000214624","journal-title":"Neurology"},{"issue":"34","key":"9422_CR16","doi-asserted-by":"publisher","first-page":"7724","DOI":"10.1523\/jneurosci.4944-04.2005","volume":"25","author":"DE Naylor","year":"2005","unstructured":"Naylor DE, Liu H, Wasterlain CG (2005) Trafficking of GABA(A) receptors, loss of inhibition, and a mechanism for pharmacoresistance in status epilepticus. J Neurosci 25(34):7724\u20137733. https:\/\/doi.org\/10.1523\/jneurosci.4944-04.2005","journal-title":"J Neurosci"},{"issue":"4","key":"9422_CR17","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1002\/epi4.70083","volume":"10","author":"HG Steier","year":"2025","unstructured":"Steier HG, Schultz CR, Niquet J et al (2025) Perampanel as a second-line therapy to midazolam reduces soman-induced status epilepticus and neurodegeneration in rats. Epilepsia Open 10(4):1187\u20131198. https:\/\/doi.org\/10.1002\/epi4.70083","journal-title":"Epilepsia Open"},{"key":"9422_CR18","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.yebeh.2018.07.004","volume":"86","author":"F Brigo","year":"2018","unstructured":"Brigo F, Lattanzi S, Rohracher A et al (2018) Perampanel in the treatment of status epilepticus: a systematic review of the literature. Epilepsy Behav 86:179\u2013186. https:\/\/doi.org\/10.1016\/j.yebeh.2018.07.004","journal-title":"Epilepsy Behav"},{"issue":"4","key":"9422_CR19","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1111\/ane.13061","volume":"139","author":"A Strzelczyk","year":"2019","unstructured":"Strzelczyk A, Knake S, K\u00e4lvi\u00e4inen R et al (2019) Perampanel for treatment of status epilepticus in Austria, Finland, Germany, and Spain. Acta Neurol Scand 139(4):369\u2013376. https:\/\/doi.org\/10.1111\/ane.13061","journal-title":"Acta Neurol Scand"},{"key":"9422_CR20","doi-asserted-by":"publisher","first-page":"108583","DOI":"10.1016\/j.yebeh.2022.108583","volume":"128","author":"DQ Perez","year":"2022","unstructured":"Perez DQ, Espiritu AI, Jamora RDG (2022) Perampanel in achieving status epilepticus cessation: a systematic review. Epilepsy Behav 128:108583. https:\/\/doi.org\/10.1016\/j.yebeh.2022.108583","journal-title":"Epilepsy Behav"},{"issue":"1","key":"9422_CR21","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1111\/epi.12865","volume":"56","author":"PN Patsalos","year":"2015","unstructured":"Patsalos PN (2015) The clinical pharmacology profile of the new antiepileptic drug perampanel: a novel noncompetitive AMPA receptor antagonist. Epilepsia 56(1):12\u201327. https:\/\/doi.org\/10.1111\/epi.12865","journal-title":"Epilepsia"},{"issue":"Suppl 2","key":"9422_CR22","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1111\/epi.14492","volume":"59","author":"S Beretta","year":"2018","unstructured":"Beretta S, Padovano G, Stabile A et al (2018) Efficacy and safety of perampanel oral loading in postanoxic super-refractory status epilepticus: a pilot study. Epilepsia 59(Suppl 2):243\u2013248. https:\/\/doi.org\/10.1111\/epi.14492","journal-title":"Epilepsia"},{"key":"9422_CR23","doi-asserted-by":"publisher","first-page":"109826","DOI":"10.1016\/j.yebeh.2024.109826","volume":"156","author":"G Bruschi","year":"2024","unstructured":"Bruschi G, Pellegrino L, Bisogno AL et al (2024) Use of perampanel oral suspension for the treatment of refractory and super-refractory status epilepticus. Epilepsy Behav 156:109826. https:\/\/doi.org\/10.1016\/j.yebeh.2024.109826","journal-title":"Epilepsy Behav"},{"issue":"4","key":"9422_CR24","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1002\/epi4.12804","volume":"8","author":"R Hanaya","year":"2023","unstructured":"Hanaya R, Kubota Y, Mizobuchi M et al (2023) Intravenous perampanel as an alternative to the oral formulations in Japanese patients with epilepsy. Epilepsia Open 8(4):1369\u20131382. https:\/\/doi.org\/10.1002\/epi4.12804","journal-title":"Epilepsia Open"},{"key":"9422_CR25","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.seizure.2025.07.023","volume":"131","author":"Y Sato","year":"2025","unstructured":"Sato Y, Iwami K, Okumura E et al (2025) Intravenous perampanel in clinical practice: a multicenter prospective registry study. Seizure 131:334\u2013339. https:\/\/doi.org\/10.1016\/j.seizure.2025.07.023","journal-title":"Seizure"},{"issue":"5","key":"9422_CR26","doi-asserted-by":"publisher","first-page":"e00063","DOI":"10.1002\/prp2.63","volume":"2","author":"T Hanada","year":"2014","unstructured":"Hanada T, Ido K, Kosasa T (2014) Effect of perampanel, a novel AMPA antagonist, on benzodiazepine-resistant status epilepticus in a lithium-pilocarpine rat model. Pharmacol Res Perspect 2(5):e00063. https:\/\/doi.org\/10.1002\/prp2.63","journal-title":"Pharmacol Res Perspect"},{"key":"9422_CR27","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.eplepsyres.2017.06.002","volume":"137","author":"T Wu","year":"2017","unstructured":"Wu T, Ido K, Osada Y, Kotani S, Tamaoka A, Hanada T (2017) The neuroprotective effect of perampanel in lithium-pilocarpine rat seizure model. Epilepsy Res 137:152\u2013158. https:\/\/doi.org\/10.1016\/j.eplepsyres.2017.06.002","journal-title":"Epilepsy Res"},{"issue":"4","key":"9422_CR28","doi-asserted-by":"publisher","first-page":"2508","DOI":"10.1007\/s12035-018-1230-6","volume":"56","author":"H Mohammad","year":"2019","unstructured":"Mohammad H, Sekar S, Wei Z, Moien-Afshari F, Taghibiglou C (2019) Perampanel but not amantadine prevents behavioral alterations and epileptogenesis in pilocarpine rat model of status epilepticus. Mol Neurobiol 56(4):2508\u20132523. https:\/\/doi.org\/10.1007\/s12035-018-1230-6","journal-title":"Mol Neurobiol"},{"issue":"10","key":"9422_CR29","doi-asserted-by":"publisher","first-page":"108061","DOI":"10.1016\/j.isci.2023.108061","volume":"26","author":"JD Garcia","year":"2023","unstructured":"Garcia JD, Wolfe SE, Stewart AR et al (2023) Distinct mechanisms drive sequential internalization and degradation of GABAARs during global ischemia and reperfusion injury. iScience. 26(10):108061. https:\/\/doi.org\/10.1016\/j.isci.2023.108061","journal-title":"iScience."},{"key":"9422_CR30","doi-asserted-by":"publisher","first-page":"104848","DOI":"10.1016\/j.nbd.2020.104848","volume":"140","author":"P Mazzocchetti","year":"2020","unstructured":"Mazzocchetti P, Mancini A, Sciaccaluga M et al (2020) Low doses of perampanel protect striatal and hippocampal neurons against in vitro ischemia by reversing the ischemia-induced alteration of AMPA receptor subunit composition. Neurobiol Dis 140:104848. https:\/\/doi.org\/10.1016\/j.nbd.2020.104848","journal-title":"Neurobiol Dis"},{"issue":"1","key":"9422_CR31","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s10571-016-0341-8","volume":"37","author":"T Chen","year":"2017","unstructured":"Chen T, Dai S-H, Jiang Z-Q et al (2017) The AMPAR antagonist perampanel attenuates traumatic brain injury through anti-oxidative and anti-inflammatory activity. Cell Mol Neurobiol 37(1):43\u201352. https:\/\/doi.org\/10.1007\/s10571-016-0341-8","journal-title":"Cell Mol Neurobiol"},{"issue":"2","key":"9422_CR32","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1212\/con.0000000000001103","volume":"28","author":"E Trinka","year":"2022","unstructured":"Trinka E, Leitinger M (2022) Management of status epilepticus, refractory status epilepticus, and super-refractory status epilepticus. Continuum (Minneap Minn) 28(2):559\u2013602. https:\/\/doi.org\/10.1212\/con.0000000000001103","journal-title":"Continuum (Minneap Minn)"},{"issue":"1","key":"9422_CR33","doi-asserted-by":"publisher","first-page":"48","DOI":"10.5698\/1535-7597-16.1.48","volume":"16","author":"T Glauser","year":"2016","unstructured":"Glauser T, Shinnar S, Gloss D et al (2016) Evidence-based guideline: treatment of convulsive status epilepticus in children and adults: report of the guideline committee of the American Epilepsy Society. Epilepsy Curr 16(1):48\u201361. https:\/\/doi.org\/10.5698\/1535-7597-16.1.48","journal-title":"Epilepsy Curr"},{"issue":"1","key":"9422_CR34","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s12028-012-9695-z","volume":"17","author":"GM Brophy","year":"2012","unstructured":"Brophy GM, Bell R, Claassen J et al (2012) Guidelines for the evaluation and management of status epilepticus. Neurocrit Care 17(1):3\u201323. https:\/\/doi.org\/10.1007\/s12028-012-9695-z","journal-title":"Neurocrit Care"},{"issue":"6","key":"9422_CR35","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1111\/epi.17982","volume":"65","author":"L Vignatelli","year":"2024","unstructured":"Vignatelli L, Tontini V, Meletti S et al (2024) Clinical practice guidelines on the management of status epilepticus in adults: a systematic review. Epilepsia 65(6):1512\u20131530. https:\/\/doi.org\/10.1111\/epi.17982","journal-title":"Epilepsia"},{"issue":"1","key":"9422_CR36","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.annemergmed.2024.02.018","volume":"84","author":"MD Smith","year":"2024","unstructured":"Smith MD, Sampson CS, Wall SP et al (2024) Clinical policy: critical issues in the management of adult patients presenting to the emergency department with seizures: approved by the ACEP board of directors, April 17, 2024. Ann Emerg Med 84(1):e1\u2013e12. https:\/\/doi.org\/10.1016\/j.annemergmed.2024.02.018","journal-title":"Ann Emerg Med"},{"issue":"5","key":"9422_CR37","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1177\/1535759720928269","volume":"20","author":"DG Vossler","year":"2020","unstructured":"Vossler DG, Bainbridge JL, Boggs JG et al (2020) Treatment of refractory convulsive status epilepticus: a comprehensive review by the American Epilepsy Society Treatments Committee. Epilepsy Curr 20(5):245\u2013264. https:\/\/doi.org\/10.1177\/1535759720928269","journal-title":"Epilepsy Curr"},{"key":"9422_CR38","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.nbd.2017.04.019","volume":"104","author":"J Niquet","year":"2017","unstructured":"Niquet J, Baldwin R, Norman K, Suchomelova L, Lumley L, Wasterlain CG (2017) Simultaneous triple therapy for the treatment of status epilepticus. Neurobiol Dis 104:41\u201349. https:\/\/doi.org\/10.1016\/j.nbd.2017.04.019","journal-title":"Neurobiol Dis"},{"issue":"2","key":"9422_CR39","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1007\/s10072-024-07798-w","volume":"46","author":"R Renna","year":"2025","unstructured":"Renna R, Andreone V, Barone P, Penza P (2025) Effectiveness and safety of perampanel in refractory status epilepticus: a case series. Neurol Sci 46(2):879\u2013885. https:\/\/doi.org\/10.1007\/s10072-024-07798-w","journal-title":"Neurol Sci"},{"key":"9422_CR40","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.pediatrneurol.2025.03.011","volume":"167","author":"AA Othman","year":"2025","unstructured":"Othman AA, Sadek AA, Ahmed EA, Abdelkreem E (2025) Combined ketamine and midazolam versus midazolam alone for initial treatment of pediatric generalized convulsive status epilepticus (Ket-Mid study): a randomized controlled trial. Pediatr Neurol 167:24\u201332. https:\/\/doi.org\/10.1016\/j.pediatrneurol.2025.03.011","journal-title":"Pediatr Neurol"},{"key":"9422_CR41","doi-asserted-by":"publisher","first-page":"110655","DOI":"10.1016\/j.yebeh.2025.110655","volume":"172","author":"R Qu","year":"2025","unstructured":"Qu R, Han A, Meng L, Qu X, Zhu Y, Dai Y (2025) Efficacy and safety of perampanel in critically ill pediatric patients with refractory and super-refractory status epilepticus: a retrospective study from a Chinese tertiary medical center. Epilepsy Behav 172:110655. https:\/\/doi.org\/10.1016\/j.yebeh.2025.110655","journal-title":"Epilepsy Behav"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-026-09422-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-026-09422-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-026-09422-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T02:02:40Z","timestamp":1793671360000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-026-09422-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,24]]},"references-count":41,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["9422"],"URL":"https:\/\/doi.org\/10.1007\/s10072-026-09422-5","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,24]]},"assertion":[{"value":"25 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable. Ethical approval was not required as the study is a review of previously published studies.","order":1,"name":"Ethics","label":"Ethics approval and institutional review board statement","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"We confirm that we have read the Journal\u2019s position on issues involved in ethical publication and affirm that this report is consistent with those guidelines.","order":2,"name":"Ethics","label":"Ethical publication statement","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None of the authors has any conflict of interest to disclose.","order":3,"name":"Ethics","label":"Conflicts of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. This article is a review and does not involve human participants or identifiable patient data.","order":4,"name":"Ethics","label":"Informed consent","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"808"}}